SpeeDx Build Further Coverage in SARS-CoV-2 Genotyping Reagent Portfolio
Rapid development of key mutation detection reagents continues to facilitate critical investigation and monitoring activities
SYDNEY--(Business Wire / Korea Newswire) October 07, 2021 -- SpeeDx Pty. Ltd., a developer of innovative molecular diagnostic solutions, have further expanded their product line of research reagents for COVID-19 variant analysis to include a key characteristic mutation connected to the SARS-CoV-2 Lambda variant of interest (VOI). The PlexPrime® SARS-CoV-2 Genotyping[*] product line has rapidly expanded since launching in July, utilising the company’s unique universal substrate approach and patented multiplexing technology. The suite of products can be used independently or combined to support laboratory investigation and monitoring efforts of key SARS-CoV-2 variants of interest or concern.
“Rapid screening of positive samples with a PCR-based approach allows laboratories to easily monitor mutations as they circulate” said Dr Charles Cartwright, SpeeDx Senior Vice President of Clinical Affairs. “The individual mutations targeted with our suite of genotyping reagents have been carefully chosen to represent key lineage divergence, thus we are finding that even the latest emerging variants of interest and concern can be targeted for further analysis with our existing portfolio.”
PlexPrime® SARS-CoV-2 L452Q Lambda[*] is a single well mix designed to detect the L452Q spike mutation of SARS-CoV-2 found in the C.37 variant of interest (Lambda), in addition to an RdRp gene target of SARS-CoV-2. This reagent is the third product in the PlexPrime® SARS-CoV-2 Genotyping portfolio and can be used as a stand-alone reflex or combined with PlexPrime® SARS-CoV-2 Alpha/Beta/Gamma+, and/or the PlexPrime®P681R Delta reagents. Compatible with standard qPCR and liquid handling instrumentation, the PlexPrime® SARS-CoV-2 Genotyping will reduce the costs and manual processes for laboratories currently practicing high-volume sequence analysis.
Founded in 2009, SpeeDx is an Australian-based private company with subsidiary offices in Austin and London, and distributors across Europe. SpeeDx specializes in molecular diagnostic solutions that go beyond simple detection to offer comprehensive information for improved patient management. Innovative real-time polymerase chain reaction (qPCR) technology has driven market-leading multiplex detection and priming strategies. Product portfolios focus on multiplex diagnostics for sexually transmitted infection (STI), antibiotic resistance markers, and respiratory disease. For more information on SpeeDx please see: https://plexpcr.com
[*] available as Research Use Only reagents not for use in diagnostic procedures
 Tracking SARS-CoV-2 variants. World Health Organisation. Found at: https://www.who.int/en/activities/tracking-SARS-CoV-2-variants/
View source version on businesswire.com: https://www.businesswire.com/news/home/20211005006261/en/
Global Marketing Director
+61 406 582 808
This is a news release distributed by Korea Newswire on behalf of this company. Learn more